Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
Schuler M, Hense J, Darwiche K, Michels S, Hautzel H, Kobe C, Lueong S, Metzenmacher M, Herold T, Zaun G, Laue K, Drzezga A, Theegarten D, Nensa F, Wolf J, Herrmann K, Wiesweg M. Schuler M, et al. Among authors: wiesweg m. J Nucl Med. 2024 Apr 4:jnumed.123.266979. doi: 10.2967/jnumed.123.266979. Online ahead of print. J Nucl Med. 2024. PMID: 38575188
PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
Guberina M, Poettgen C, Metzenmacher M, Wiesweg M, Schuler M, Aigner C, Ploenes T, Umutlu L, Gauler T, Darwiche K, Stamatis G, Theegarten D, Hautzel H, Jentzen W, Guberina N, Herrmann K, Eberhardt WEE, Stuschke M. Guberina M, et al. Among authors: wiesweg m. J Nucl Med. 2021 May 20;62(12):1684-91. doi: 10.2967/jnumed.120.260646. Online ahead of print. J Nucl Med. 2021. PMID: 34016730 Free PMC article.
SUVmax Above 20 in 18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary.
Zaun G, Weber M, Metzenmacher M, Wiesweg M, Hilser T, Zaun Y, Liffers S, Pogorzelski M, Virchow I, Eberhardt W, Theurer S, Sabbah TA, Reissig TM, Stuschke M, Kürten C, Hussain T, Lang S, Kasper S, Fendler WP, Herrmann K, Schuler M. Zaun G, et al. Among authors: wiesweg m. J Nucl Med. 2023 Aug;64(8):1191-1194. doi: 10.2967/jnumed.122.265161. Epub 2023 Jun 15. J Nucl Med. 2023. PMID: 37321823
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.
Kersting D, Sandach P, Sraieb M, Wiesweg M, Metzenmacher M, Darwiche K, Oezkan F, Bölükbas S, Stuschke M, Umutlu L, Nader M, Hamacher R, Fendler WP, Wienker J, Eberhardt WEE, Schuler M, Herrmann K, Hautzel H. Kersting D, et al. Among authors: wiesweg m. J Nucl Med. 2023 Oct;64(10):1540-1549. doi: 10.2967/jnumed.123.265664. Epub 2023 Jul 20. J Nucl Med. 2023. PMID: 37474272
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, Kühl H, Stuschke M, Schmid KW, Schuler M. Wiesweg M, et al. J Thorac Oncol. 2017 Jan;12(1):54-64. doi: 10.1016/j.jtho.2016.08.137. Epub 2016 Aug 27. J Thorac Oncol. 2017. PMID: 27575422 Free article.
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
Reis H, Metzenmacher M, Goetz M, Savvidou N, Darwiche K, Aigner C, Herold T, Eberhardt WE, Skiba C, Hense J, Virchow I, Westerwick D, Bogner S, Ting S, Kasper S, Stuschke M, Nensa F, Herrmann K, Hager T, Schmid KW, Schuler M, Wiesweg M. Reis H, et al. Among authors: wiesweg m. Clin Lung Cancer. 2018 Jul;19(4):e441-e463. doi: 10.1016/j.cllc.2018.03.010. Epub 2018 Mar 17. Clin Lung Cancer. 2018. PMID: 29631966
Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations.
Metzenmacher M, Goetz M, Herold T, Stuschke M, Aigner C, Darwiche K, Eberhardt WE, Schuler M, Wiesweg M. Metzenmacher M, et al. Among authors: wiesweg m. Clin Lung Cancer. 2021 Sep;22(5):e668-e672. doi: 10.1016/j.cllc.2020.11.008. Epub 2020 Dec 2. Clin Lung Cancer. 2021. PMID: 33551244 No abstract available.
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
Scheffler M, Wiesweg M, Michels S, Nogová L, Kron A, Herold T, Scheel AH, Metzenmacher M, Eberhardt WE, Reis H, Fassunke J, Darwiche K, Aigner C, Schaufler D, Riedel R, Fischer R, Koleczko S, Schildhaus HU, Merkelbach-Bruse S, Schmid KW, Büttner R, Wolf J, Schuler M. Scheffler M, et al. Among authors: wiesweg m. Lung Cancer. 2022 Jun;168:10-20. doi: 10.1016/j.lungcan.2022.04.006. Epub 2022 Apr 16. Lung Cancer. 2022. PMID: 35461051
56 results